Pipeline

Sorrento's R&D wa ni idojukọ lori imotuntun awakọ ni COVID-19, itọju alakan, iṣakoso irora ni kikun ati awọn aarun autoimmune

Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
Awọn eto COVID-19  

COVISTIX™ (aisan ayẹwo) Dekun Antijeni igbeyewo

*

Aṣẹ Lilo pajawiri (EUA) ni Mexico (COFEPRIS), Brazil (ANVISA), ati CE Ti samisi ni Yuroopu

COVIMARK™ (aisan ayẹwo) Dekun Antijeni igbeyewo

*

Ohun elo ti a fi silẹ ni AMẸRIKA ati Kanada fun Aṣẹ Lilo pajawiri (EUA)

COVISHIELD™ (itọju) Antibody Neutralizing (IN) ni Awọn Alaisan ati Awọn Alabojuto

40%*

COVISHIELD™ (itọju) Antibody Neutralizing (IV) ni Awọn Alaisan ati Awọn Alabojuto

20%*

FUJOVEE™ (Abivertinib) COVID-19 to lagbara ni Awọn alaisan ICU

82%*

Idanwo pataki ni isunmọtosi imukuro FDA

OQORY™ (COVI-MSC) ARDS nitori COVID-19 ni Awọn alaisan ICU

82%*

Idanwo pataki ni Ilu Brazil

Mpro Olugbeja (ògùn ẹnu) Alatako-ọlọjẹ

40%*

Omicron mRNA ajesara Ajesara

20%*

Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
ajẹsara  

FUJOVEE™ (Abivertinib) NSCLC

82%*

FUJOVEE™ (Abivertinib) B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) Ibo ori

20%*

FUJOVEE™ (Abivertinib) lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) GvHD

20%*

PD-L1 (Socazolimab)* SCLC

82%*

* Ni Ajọṣepọ pẹlu Lee's Pharm ni Ilu China

PD-L1 (STI-3031)** obo akàn

82%*

** Ni AMẸRIKA ati ni ajọṣepọ pẹlu ImmuneOncia ni Koria

CD47 Awọn èèmọ to lagbara

40%*

CD38 DAR-T Ọpọlọ Myeloma

40%*

CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal

40%*

TROP2 ADC* Awọn èèmọ to lagbara

40%*

* Ni Ilu China

Seprehvec™ oncolytic kokoro Awọn èèmọ to lagbara; Awọn èèmọ CNS

40%*

BMA ADC Awọn èèmọ olomi

20%*

Bevacizumab-ADNAB™ Ọgbẹ ti ipilẹṣẹ

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic

Bevacizumab-ADNAB™ Ovarian Cancer

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic

Rituximab-ADNAB™ B-cell Lymphomas

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic
Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
irora  

ZTlido™ 1.8%
Neuralgia Postherpetic - PHN

99.8%*

SP-102 (SEMDEXA) Lumbar Radicular/Irora Sciatica

82%*

SP-103 (Eto Ipilẹ Lidocaine 5.4%) Irora Pada irora

20%*

SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Fibromyalgia

20%*

RTX (resiniferatoxin)
Abẹrẹ epidural
Irora ti ko le fa ni Ilọsiwaju Akàn

60.3%*

Orphan yiyan

RTX (resiniferatoxin)
Ona-intra-articular
Iwontunwonsi si Irora Orunkun Okun

60.2%*

Awọn eto bọtini Ifarahan Preclinical Igbese I Igbese II Ipele III/Pivotal FDA Approval
Ifijiṣẹ Lymphatic  

Sofusa® egboogi-TNF Aifọwọyi (RA)

40%*

Sofusa® egboogi-PD-1 Ẹjẹ T-Cell Lymphoma (CTCL)

40%*

Sofusa® egboogi-CTLA-4 Melanoma

40%*

Ni ajọṣepọ pẹlu awọn Mayo Clinic
Awọn eto COVID-19
Awọn eto bọtini (Itọkasi) alakoso
COVISTIX™ (aisan ayẹwo) FDA EUA
COVIMARK™ (aisan ayẹwo) FDA EUA
COVISHIELD™ (itọju) PH I
COVISHIELD™ (itọju) Preclinical
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
Inhibitor Mpro (ògùn ẹnu) (agbogun ti gbogun ti) Ph I
Omicron mRNA ajesara (ajesara) Preclinical
ajẹsara
Awọn eto bọtini (Itọkasi) alakoso
FUJOVEE™ (Abivertinib) (NSCLC) Ph III
FUJOVEE™ (Abivertinib) (Awọn lymphomas sẹẹli B) Ph II
FUJOVEE™ (Abivertinib) (Prostate) Preclinical
FUJOVEE™ (Abivertinib) ( Lupus) Preclinical
FUJOVEE™ (Abivertinib) (MS) Preclinical
FUJOVEE™ (Abivertinib) (GvHD) Preclinical
PD-L1 (Socazolimab)*(SCLC) Ph III
PD-L1 (STI-3031)** (Akàn Akàn) Ph III
CD47 (Awọn èèmọ to lagbara) Ph I
CD38 DAR-T (Ọpọ Myeloma) Ph I
CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal) Ph I
TROP2 ADC* (Awọn èèmọ to lagbara) Ph I
Seprehvec™ oncolytic kokoro (Awọn èèmọ to lagbara; Awọn èèmọ CNS) PH I
BMA ADC (Awọn èèmọ olomi) Preclinical
Bevacizumab-ADNAB™ (Akàn Endometrial) Ph I
Bevacizumab-ADNAB™ (Akàn Ovarian) Ph I
Rituximab-ADNAB™ (Lymphomas B-cell) Ph I
irora
Awọn eto bọtini (Itọkasi) alakoso
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval
SP-102 (SEMDEXA) Ph III
SP-103 (Eto Ipilẹ Lidocaine 5.4%) Preclinical
SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Preclinical
RTX (resiniferatoxin) Abẹrẹ apọju (Irora ti ko le fa ninu akàn To ti ni ilọsiwaju) Ph II
RTX (resiniferatoxin) ipa-ọna inu-articular (Iwọntunwọnsi si Irora Orunkun OA lile) Ph II
Ifijiṣẹ Lymphatic
Awọn eto bọtini (Itọkasi) Igbese II
Sofusa® egboogi-TNF (Autoimmune RA) Ph I
Sofusa® egboogi-PD-1 T-Cell Lymphoma (CTCL)) Ph I
Sofusa® egboogi-CTLA-4 (Melanoma) Ph I